Tuesday, January 17, 2017 3:50:17 PM
BEVERLY, Mass., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, responds to the latest defamatory article published today on Seeking Alpha by the short-selling anonymous author going only by the name Mako Research.
As with Mako’s prior article on Cellceutix, the non-credible criminal author makes countless unfounded, wild allegations about the Company. The purpose of the iniquitous writings of Mako is to scare shareholders and drive CTIX stock lower for the profit of the author and all organizations collaborating in the illegal and manipulative market activity often called, “short and distort.”
The original article served as the foundation for a class action lawsuit, which was dismissed by the court with prejudice, as there was no truth in Mako’s so-called “research.” The entire legal case discrediting Mako can be viewed at:
http://ia601507.us.archive.org/4/items/gov.uscourts.nysd.447344/gov.uscourts.nysd.447344.docket.html.
“Mako is a pawn in an organized criminal enterprise that profits tremendously from this type of fake news that Seeking Alpha relishes publishing because it drives web traffic. There’s a reason that the courts have ruled that Seeking Alpha is not a credible news source,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix. “We will continue to gather information on Mako and his co-conspirators.”
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM